The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

The randomized, double‐blind, double‐dummy, phase 3b RELIEF trial evaluated polycythaemia vera (PV)‐related symptoms in patients who were well controlled with a stable dose of hydroxycarbamide (also termed hydroxyurea) but reported PV‐related symptoms. Patients were randomized 1:1 to ruxolitinib 10 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesa, Ruben, Vannucchi, Alessandro M., Yacoub, Abdulraheem, Zachee, Pierre, Garg, Mamta, Lyons, Roger, Koschmieder, Steffen, Rinaldi, Ciro, Byrne, Jennifer, Hasan, Yasmin, Passamonti, Francesco, Verstovsek, Srdan, Hunter, Deborah, Jones, Mark M., Zhen, Huiling, Habr, Dany, Martino, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215488/
https://www.ncbi.nlm.nih.gov/pubmed/27858987
http://dx.doi.org/10.1111/bjh.14382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215488/
https://www.ncbi.nlm.nih.gov/pubmed/27858987
http://dx.doi.org/10.1111/bjh.14382

Ejemplares similares